Financial Results, Positive Clinical Trial Data, Medicare Plan Ratings, and Arbitration Awards - Research Report on UnitedHealth

 Financial Results, Positive Clinical Trial Data, Medicare Plan Ratings, and
  Arbitration Awards - Research Report on UnitedHealth Group, Humana, Align,
                              Sanofi, and Anacor

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, October 23, 2013

NEW YORK, October 23, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting
UnitedHealth Group Inc. (NYSE: UNH), Humana Inc. (NYSE: HUM), Align
Technology, Inc. (NASDAQ: ALGN), Sanofi SA (ADR) (NYSE: SNY) and Anacor
Pharmaceuticals Inc. (NASDAQ: ANAC). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

UnitedHealth Group Inc. Research Report

On October 17, 2013, UnitedHealth Group, Inc. (UnitedHealth Group) reported
its Q3 2013 results. The Company stated that its total revenues increased
12.2% YoY to $30.6 billion during the quarter, and its net earnings
attributable to common shareholders increased marginally by 0.8% YoY to $1.6
billion. Diluted EPS per share came in at $1.53 in Q3 2013, compared to $1.50
per diluted share in Q3 2012. Commenting on the results, Stephen J. Hemsley,
President and CEO of UnitedHealth Group, said, "We are pleased to have grown
and advanced by serving individual health care needs and the ever-changing
demands of the health care system at large." The Company also stated that it
has narrowed its outlook for full-year 2013 net earnings to $5.40 - $5.50 per
share. The Full Research Report on UnitedHealth Group Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/73e5_UNH]

--

Humana Inc. Research Report

On October 17, 2013, Humana Inc. (Humana) announced that it has achieved
strong Medicare Stars Quality Ratings for its Medicare Advantage (MA) plans.
The Company stated that these Humana MA plans, available to Medicare
beneficiaries during the Medicare Annual Election Period (AEP), which began on
October 15, 2013 and runs through December 7, 2013, will take effect on
January 1, 2014. Humana added that many of its MA plans that will be available
in 2014 have higher Medicare Stars quality ratings than in years past. Humana
informed that it has 18 MA plans that achieved a rating of 4.0 stars or
greater. Further, the Company said that 55% of 2013 Humana MA Membership is
participating in 2014 plans rated 4.0 stars or greater. Humana is also
offering nine MA plans that achieved a 4.5 star rating. Lastly, Humana stated
that its MA HMO plans in Florida, Mississippi, North Carolina, and Oregon were
again rated 4.5 stars. The Full Research Report on Humana Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/496b_HUM]

--

Align Technology, Inc. Research Report

On October 17, 2013, Align Technology, Inc. (Align Technology) announced its
Q3 2013 financial results. The Company reported that its net revenues
increased 20.5% YoY to $164.5 million during the quarter. Align Technology
stated that its net profit stood at $34.5 million or $0.42 per diluted share
in Q3 2013, compared to net loss of $0.3 million or $0.00 per diluted share in
Q3 2012. Commenting on the results, Thomas M. Prescott, Align Technology's
President and CEO, said, "The third quarter includes a seasonally slower
period in Europe and in North America for our GP dentists, along with the peak
of the summer season for teenage orthodontic case starts. We're pleased that
patient traffic appears to have remained solid for our North American
Orthodontist customers this summer, which resulted in strong sequential and
year over year growth for Invisalign volume, especially in the important
teenage segment." The Full Research Report on Align Technology, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/69b3_ALGN]

--

Sanofi SA (ADR) Research Report

On October 16, 2013, Sanofi SA (ADR) (Sanofi) and Regeneron Pharmaceuticals
(Regeneron) announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an
investigational monoclonal antibody targeting PCSK9 (proprotein convertase
subtilisin/kexin type 9) met its primary efficacy endpoint. Sanofi stated that
the mean low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol)
reduction from baseline to week 24, the primary efficacy endpoint of the
study, was significantly greater in patients randomized to alirocumab, in
comparison to patients randomized to ezetimibe (47.2% vs. 15.6%, p<0.0001).
Sanofi added that in the trial, which employed a dose increase (up-titration)
for patients who did not achieve LDL-C level of 70 milligrams/deciliter
(mg/dL), the majority of patients remained on the initial low dose of
alirocumab of 75 mg. The Full Research Report on Sanofi SA (ADR) - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/29ea_SNY]

--

Anacor Pharmaceuticals Inc. Research Report

On October 17, 2013, Anacor Pharmaceuticals Inc. (Anacor) announced that the
arbitrator appointed to resolve its dispute with Valeant Pharmaceuticals, Inc.
(Valeant) successor in interest to Dow Pharmaceutical Sciences, Inc. (DPS),
has issued an Interim Final Award in favor of Anacor, and that it has been
awarded $100 million in damages as well as all costs of the arbitration and
reasonable attorney's fees. The Company stated that the Final Award will be
submitted to the court of appropriate jurisdiction for confirmation and
enforcement. Anacor said that the timeframe for this legal process is subject
to the court's time schedule, but the Company expects confirmation of the
award before the end of 2013, at which point the judgment will become
enforceable. The Full Research Report on Anacor Pharmaceuticals Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/05d8_ANAC]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.